**Chapter 6**

*Multiple Myeloma*

or myeloid cells surface antigens [II]: CD22, CD30, CD33, CD38, CD40, SLAMF-7 and CCR4). Clin Microbiol Infect. 2018 Jun;24 Suppl 2:S83-S94.

Christiansen MLS, et al. EMA Review of Daratumumab for the Treatment of Adult Patients with Multiple Myeloma. The Oncologist. 2018; 23:594-602.

[45] Tzogani K, Penninga E,

[46] Chapuy CI, Nicholson RT, Aguad MD, et al. Resolving the daratumumab interference with blood compatibility testing. Transfusion. 2015;

[47] McCudden C, Axel AE, Slaets D, et al. Monitoring multiple myeloma patients treated with daratumumab: teasing out monoclonal antibody interference. Clin Chem Lab Med 2016;

[48] Ma X, Wong SW, Zhou P, et al. Daratumumab binds to mobilized CD34+ cells of myeloma patients in vitro without cytotoxicity or impaired progenitor cell growth. Exp Hematol

[49] Plesner T, van de Donk N, Richardson PG. Controversy in the Use of CD38 Antibody for Treatment of Myeloma: Is High CD38 Expression Good or Bad? Cells. 2020 Feb 6;9(2):378.

55:1545-54.

54:1095-104.

Oncol. 2018;7:27.

**82**
